Research.Patient.info

non-metastatic (borderline) resectable pancreatic cancer research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingTherapeutic confirmatory (Phase III)
THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)
This study looks at two different ways to treat pancreatic cancer that can or might be surgically removed. It compares using a specific combination of powerful medicines before surgery to another powerful medicine combined with radiation before surgery, followed by more medicine. The main goal is to see which treatment helps people live longer.
Netherlands